Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 4% in early trading, sales volume surged more than 3 times in the first half of the year after incorporating medical insurance, and platinib

The Zhitong Finance App learned that Cornerstone Pharmaceutical-B (02616) rose more than 4% in early trading. As of press release, it rose 4.73% to HK$5.975, with a turnover of HK$11.528,800.

According to the news, Cornerstone Pharmaceuticals announced its interim results, with revenue of 205 million yuan in the first half of the year, an increase of 314.75% over the previous year. Among them, drug sales revenue was 183 million yuan, mainly from platinib, avatinib, and suglizumab. Since Platinib was included in the national health insurance catalogue in January 2026, in-hospital sales increased by nearly 500% year-on-year as of July 2026, becoming the main driving force for revenue growth.

It is worth noting that recently, in the results of Hang Seng Index's recent quarterly review, Cornerstone Pharmaceutical-B was included in the Hang Seng Composite Index. Changes in the Hang Seng Composite Index will be implemented after the market closes on September 4 and will take effect on September 7. At that time, the Shanghai and Shenzhen Stock Exchange will adjust the scope of investment targets of Hong Kong Stock Connect accordingly. Cornerstone Pharmaceutical-B may be transferred to the Hong Kong Stock Connect because it meets a range of standards including market value and liquidity.